|
[1]
|
Mallol, J., Crane, J., von Mutius, E., et al. (2013) The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A Global Synthesis. Allergologia et Immunopathologia (Madr), 41, 73-85. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
刘传合, 洪建国, 尚云晓, 等. 中国16城市儿童哮喘患病率20年对比研究[J]. 中国实用儿科杂志, 2015, 30(8): 596-600.
|
|
[3]
|
Global Initiative for Asthma (2020) Global Strategy for Asthma Management and Prevention.
https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf
|
|
[4]
|
Cloutier, M.M., Dixon, A.E., Krishnan, J.A., et al. (2020) Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update from the National Asthma Education and Prevention Program. JAMA, 324, 2301-2317. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Denlinger, L.C., Phillips, B.R., Ramratnam, S., et al. (2017) Inflam-matory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. American Journal of Res-piratory and Critical Care Medicine, 195, 302-313. [Google Scholar] [CrossRef]
|
|
[6]
|
Chung, K.F., Godard, P., Adelroth, E., et al. (1999) Difficult/Therapy-Resistant Asthma: The Need for an Integrated Approach to Define Clinical Phenotypes, Evaluate Risk Factors, Understand Pathophysiology and Find Novel Therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. European Respiratory Journal, 13, 1198-1208. [Google Scholar] [CrossRef]
|
|
[7]
|
American Thoracic Society (2000) Proceedings of the ATS Workshop on Refractory Asthma: Current Understanding, Recommendations, and Unanswered Questions. American Journal of Respiratory and Critical Care Medicine, 162, 2341-2351. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Bousquet, J., Mantzouranis, E., Cruz, A.A., et al. (2010) Uni-form Definition of Asthma Severity, Control, and Exacerbations: Document Presented for the World Health Organization Consultation on Severe Asthma. The Journal of Allergy and Clinical Immunology, 126, 926-938. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
支气管哮喘防治指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048.
|
|
[10]
|
Gibson, P.G., Yang, I.A., Upham, J.W., et al. (2017) Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults with Persistent Uncontrolled Asthma (AMAZES): A Randomised, Dou-ble-Blind, Placebo-Controlled Trial. The Lancet, 390, 659-668. [Google Scholar] [CrossRef]
|
|
[11]
|
Chakir, J., Haj-Salem, I., Gras, D., et al. (2015) Effects of Bronchial Thermoplasty on Airway Smooth Muscle and Collagen Deposition in Asthma. Annals of the American Tho-racic Society, 12, 1612-1618. [Google Scholar] [CrossRef]
|
|
[12]
|
Worth, H., Criée, C.P., Vogelmeier, C.F., et al. (2021) Prevalence of Overuse of Short-Acting Beta-2 Agonists (SABA) and Associated Factors among Patients with Asthma in Germany. Respiratory Research, 22, Article No. 108. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Canonica, G.W., Paggiaro, P., Blasi, F., et al. (2021) Manifesto on the Overuse of SABA in the Management of Asthma: New Approaches and New Strategies. Therapeutic Advances in Respiratory Disease, 15, 1-6. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
亓玉心, 杨文平, 刘爽, 等. 布地奈德对哮喘大鼠气道平滑肌细胞增殖及凋亡的影响[J]. 解剖学报, 2021, 52(5): 795-802.
|
|
[15]
|
应延风, 姚静婵, 胡国华. 孟鲁司特治疗儿童难治性哮喘效果研究[J]. 现代中西医结合杂志, 2007(25): 3617-3619.
|
|
[16]
|
Versiani Nunes Pinheiro de Queiroz, M., Gonçalves Alvim, C., Cruz, Á.A., et al. (2017) Lung Function in Severe Pediatric Asthma: A Longitudinal Study in Children and Adolescents in Brazil. Clinical and Translational Allergy, 7, Article No. 48. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Engeroff, P. and Vogel, M. (2021) The Role of CD23 in the Reg-ulation of Allergic Responses. Allergy, 76, 1981-1989. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Palomares, Ó., Sánchez-Ramón, S., Dávila, I., et al. (2017) How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. International Journal of Molecular Sciences, 18, 1328. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Hanania, N.A., Alpan, O., Hamilos, D.L., et al. (2011) Omalizumab in Severe Allergic Asthma Inadequately Controlled with Standard Therapy: A Randomized Trial. Annals of Internal Medi-cine, 154, 573-582. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Sztafińska, A., Gwardys, M., Podlecka, D., et al. (2021) Effectiveness of Omalizumab in Children and Adolescents with Uncontrolled Allergic Asthma: A Case Series from Poland. Postępy Dermatologii i Alergologii, 38, 427-432. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Berghea, E.C., Balgradean, M., Pavelescu, C., et al. (2021) Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma—A Romanian Per-spective. Children (Basel), 8, 1141. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Nakamura, N., Kashitani, Y., Yoshisue, H., et al. (2021) Real-Life Long-Term Safety and Effectiveness of Omalizumab in Japanese Pediatric Patients with Severe Allergic Asthma: A Post-Marketing Surveillance. Allergology International, 70, 319-326. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Odajima, H., Ebisawa, M., Nagakura, T., et al. (2015) Omalizumab in Japanese Children with Severe Allergic Asthma Uncontrolled with Standard Therapy. Allergology International, 64, 364-370. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Kim, M.K., Park, H.S., Park, C.S., et al. (2021) Efficacy and Safety of Mepolizumab in Korean Patients with Severe Eosinophilic Asthma from the DREAM and MENSA Studies. Korean Journal of Internal Medicine, 36, 362-370. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Tosca, M.A., Girosi, D., Sacco, O., et al. (2021) Steroid-sparing Effect of Mepolizumab in Children with Severe Eosinophilic Nonallergic Asthma. Allergologia et Immunopathologia (Madr), 49, 113-116. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Giovannini, M., Mori, F., Barni, S., et al. (2019) Omalizumab and Mepolizumab in the Landscape of Biological Therapy for Severe Asthma in Children: How to Choose? Italian Journal of Pediatrics, 45, Article No. 151. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
FitzGerald, J.M., Bleecker, E.R., Nair, P., et al. (2016) Benrali-zumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-On Treatment for Patients with Severe, Uncon-trolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. The Lancet, 388, 2128-2141. [Google Scholar] [CrossRef]
|
|
[28]
|
Nair, P., Wenzel, S., Rabe, K.F., et al. (2017) Oral Glucocor-ticoid-Sparing Effect of Benralizumab in Severe Asthma. New England Journal of Medicine, 376, 2448-2458. [Google Scholar] [CrossRef]
|
|
[29]
|
Ohta, K., Adachi, M., Tohda, Y., et al. (2018) Efficacy and Safety of Benralizumab in Japanese Patients with Severe, Uncontrolled Eosinophilic Asthma. Allergology International, 67, 266-272. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Castro, M., Corren, J., Pavord, I.D., et al. (2018) Dupi-lumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. New England Journal of Medicine, 378, 2486-2496. [Google Scholar] [CrossRef]
|
|
[31]
|
Rabe, K.F., Nair, P., Brusselle, G., et al. (2018) Effica-cy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England Journal of Medicine, 378, 2475-2485. [Google Scholar] [CrossRef]
|
|
[32]
|
Menzies-Gow, A., Corren, J., Bourdin, A., et al. (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New England Journal of Medicine, 384, 1800-1809. [Google Scholar] [CrossRef]
|
|
[33]
|
Ando, K., Fukuda, Y., Tanaka, A. and Sagara, H. (2022) Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Me-ta-Analysis. Cells, 11, 819. [Google Scholar] [CrossRef] [PubMed]
|